Overview

Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if dasatinib can help to control Chronic Lymphocytic Leukemia (CLL). The safety of the drug will also be studied. Optional Procedures: You will be asked to have additional blood samples drawn. These samples will be used to see how the disease is responding to the drug.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Bristol-Myers Squibb
Treatments:
Dasatinib